PM8002 Biosimilar - Research Grade

Human

VEGF + PD-L1

5mg/ml

Human IgG1(L234A/L235A/E356D/M358L)-kappa-VHH

https://www.imgt.org/mAb-DB/

ICH3002

P15692;Q9NZQ7

Blue ice

Co-targeting VEGF-driven angiogenesis and PD-L1-mediated immune evasion is a leading combination strategy in cancer research, aimed at simultaneously normalizing tumour vasculature and relieving checkpoint suppression. This research-grade PM8002-type bispecific antibody is an unconjugated, non-therapeutic reagent engineered to bind both VEGF and PD-L1 for preclinical investigation of these intertwined pathways. Validated for functional assays and supplied for research use only (RUO), it is produced to in vivo grade standards as an ultra-pure, low-endotoxin preparation. With scalable milligram (mg) to gram (g) availability, it supports in vitro screening, in vivo tumour-immunology models and dual-mechanism characterization in high-throughput laboratories.

This monoclonal antibody was purified using IEC

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.